Traders should anticipate near-term downward pressure on VRAX stock due to significant dilution from the warrant exercise. Monitor for potential exercises of the remaining 12.5 million preferred options, which could lead to further dilution if exercised or overhang if not.
Price Chart
Executive Summary
Virax Biolabs confirmed the full exercise of pre-funded warrants, adding 12.5 million ordinary shares to its outstanding share count, bringing the total to 19,923,432 shares. The exercise follows a $5 million private placement in December 2025 and results in immediate share dilution without new cash inflow.
Key Facts
- All 12,500,000 pre-funded warrants from the December 2025 $5M private placement have been exercised as of April 10, 2026.
- Exercise price was $0.0001 per share, resulting in minimal cash inflow despite significant share dilution.
- Total ordinary shares outstanding now stand at 19,923,432.
- The transaction was part of a private placement that raised $5 million in gross proceeds in December 2025.
- Preferred investment options for another 12.5 million shares remain outstanding, exercisable at $0.40 per share over five years.
Financial Impact
Approximately 12.5 million new shares issued with minimal cash received ($1,250 total from $0.0001 exercise price), increasing shares outstanding by over 100% based on prior count implied by context.
Risk Factors
- High share dilution reduces existing shareholders' equity and future earnings per share.
- Potential for further dilution if the 12.5 million preferred options are exercised.
- Low market cap ($1M) amplifies volatility risk from concentrated share issuance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-151292 |
| Document: 0001193125-26-151292-index-headers.html | 0001193125-26-151292 |
| Document: 0001193125-26-151292-index.html | 0001193125-26-151292 |
| Document: 0001193125-26-151292.txt | 0001193125-26-151292 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $1.85 | awaiting T+60 | — | $1.18 (−36.22%) |
Sep 4, 2026 7w ago | 6-K | $2.63 | awaiting T+60 | — | $1.18 (+55.13%) |
Sep 4, 2026 7w ago | EFFECT | $2.63 | awaiting T+60 | — | $1.18 (−55.05%) |
Aug 18, 2026 10w ago | 6-K | $2.76 | awaiting T+60 | — | $1.18 (−57.25%) |
Jul 31, 2026 12w ago | 6-K | $2.62 $1.19 | ▲ +54.58% | ▲ +57.04% | $1.18 (+54.96%) |
Jul 16, 2026 14w ago | 6-K | $3.90 $1.87 | ▼ −52.05% | ▼ −55.76% | $1.18 (−69.74%) |
Jul 9, 2026 15w ago | Press Release | $6.36 $2.20 | ▲ +65.41% | ▲ +67.04% | $1.18 (+81.45%) |
Jul 9, 2026 15w ago | 6-K | $6.36 $2.20 | ▼ −65.41% | ▼ −67.04% | $1.18 (−81.45%) |
Jun 24, 2026 17w ago | 6-K | $0.1350 $0.0924 | ▼ −31.56% | ▼ −36.89% | $1.18 (+774.07%) |
Jun 12, 2026 19w ago | 6-K | $0.1840 $0.1092 | ▼ −40.65% | ▼ −43.44% | $1.18 (+541.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers